Biosimilar Drugs Promise to Slash Health-Care Costs in Rich Countries
November 8, 2018
(The Economist) – “IT’S THE prices, stupid.” That simple assessment of America’s wildly expensive health-care system was made 15 years ago by Uwe Reinhardt, a health economist who died last year. Health costs as a proportion of America’s economic output have soared since, from 14.5% in 2003 to over 17% in 2017, with drug-price inflation a big culprit. Less than 2% of Americans are treated with specialty biotech drugs, but these account for as much as 35% of total drug spending. The good news is that cheaper biotech drugs are coming.